Bioadhesive Matrix Technology Platform

Next-Generation Localized Barrier for the Prolonged Treatment of Oral Mucositis

Executive Summary

Oral Mucositis (OM) represents one of the most debilitating and painful complications of oncology treatment, resulting in severe mucosal ulceration, systemic infection risks, and compromised nutritional intake. Current palliative interventions, such as standard liquid oral rinses, offer negligible therapeutic windows because they are rapidly cleared by physical tongue mechanics and physiological saliva flow.

The Phoenix Project introduces an innovative, patented technology platform (U.S. Provisional Patent Application No. 63/993,997) engineered specifically to circumvent this clearance mechanism. The platform delivers a robust, localized bioadhesive matrix designed to mechanically shield damaged tissue, optimize the therapeutic interface, and significantly extend contact time at the targeted lesion site.

The Tech Platform & Mechanics

The platform architecture provides unparalleled formulation flexibility, allowing seamless scaling into multiple clinically viable modalities to meet diverse patient compliance and clinician preference standards:

Solid Film / Topical Patch: A precise 0.3 mm engineered barrier optimized for localized, severe ulcerations.
Gel / Mucoadhesive Paste: Structured for targeted application over variable anatomical contours.
Liquid Spray: A fine, uniform plume providing broad, non-contact coverage across sensitive tissues.
Powder Delivery Matrix: In-situ activation that cross-links instantly upon contact with oral moisture.

By establishing a physical boundary that withstands standard saliva flow rates and active tongue movement, this platform maintains structural integrity directly over ulcerated tissue, drastically mitigating the direct activation of pain receptors by external stimuli.

Value Proposition for Manufacturers

IP Protection: Covered under filed U.S. Provisional Intellectual Property.
Market Differentiation: Shifts standard-of-care from transient liquid rinses to a true localized, high-retention structural matrix.
Regulatory Streamlining: Designed using biocompatible and industry-accepted polymeric components to enable an efficient regulatory pathway.

Market Analytics

40%

Chemotherapy Incidence

90%+

Head/Neck Radiation Incidence

$18K–$42K

Avg. Added Cost Per OM Patient

The massive economic burden of severe Oral Mucositis stems directly from prolonged hospitalizations, emergency opioid usage, and feeding tube dependency. A long-lasting physical barrier addresses these cost drivers directly.

Commercial Strategy

We are actively seeking strategic commercial manufacturing or licensing partners with established commercial footprints in oncology supportive care, advanced drug delivery, or oral health infrastructure.

No Grant of Rights

This page and its contents are for informational, non-confidential evaluative purposes only. No license, express or implied, under any patent, copyright, or trade secret is granted or established by the publication or review of this technical abstract.